Table 3. GEE analysis results of the 536 chronic hepatitis C patients who underwent anti-hepatitis C virus therapy.
Variants | PAI-1 (ng/ml) | |
---|---|---|
95% CI of estimated exp (β) [Estimated exp. (β)] | p-values | |
Sex (female) | 0.214~0.848 (0.426) | 0.015* |
Age | 0.939~1.012 (0.975) | 0.181 |
BMI | 1.043~1.296 (1.163) | 0.007* |
Therapy intervention (without) | 0.012~0.155 (0.043) | <0.001* |
Therapy duration | 0.841~1.346 (1.064) | 0.553 |
SVR | 0.202~1.514 (0.552) | 0.249 |
HCV genotype | 0.59~2.354 (1.178) | 0.642 |
HCV RNA (Log10 IU/ml) | 0.683~1.281 (0.935) | 0.676 |
HOMA-IR | 1.003~1.066 (1.034) | 0.003* |
ALT (U/L) | 0.994~1.004 (0.999) | 0.704 |
APRI | 1.038~1.1 (1.069) | <0.001* |
hsCRP (mg/dL) | 0.941~1.279 (1.097) | 0.235 |
WBC count (103/μL) | 0.982~1.253 (1.235) | 0.07 |
Platelets count (103/μL) | 1.018~1.033 (1.026) | <0.001* |
Hepatic steatosis (yes) | 0.569~2.014 (1.07) | 0.833 |
Liver cirrhosis (yes) | 0.596~3.476 (1.495) | 0.391 |
TC (mg/dL) | 0.972~0.998 (0.985) | 0.023* |
TGs (mg/dL) | 1.002~1.006 (1.004) | 0.001* |
PAI-1 (ng/ml) | NA | NA |
BNP (Log10 pg/mL) | 0.189~2.627 (0.704) | 0.602 |
Homocysteine (μmol/L) | 0.234~3.86 (1.234) | 0.885 |
eGFR | 1.001~1.045 (1.023) | 0.042* |
PAI-1-rs1799889 (4 G/4 G genotype) | 1.69~4.09 (2.63) | <0.001* |
IFNL3-rs12979860 (CC genotype) | 1.18~4.18 (2.22) | 0.013* |
Estimates of exp. (β), 95% confidence interval (CI) of exp. (β) and p-values for the variants that predicted PAI-1 longitudinally. GEE: generalized estimating equation; CI: confidence interval; OR: odds ratio; *p < 0.05; NA, not accessible; SVR: sustained virological response; BMI: body mass index; Log: logarithmic; HOMA-IR: homeostasis model assessment-estimated insulin resistance; ALT: alanine aminotransferase; APRI: aspartate aminotransferase to platelet ratio index; hsCRP: high sensitivity C-reactive protein; WBC: white blood cells; TC: total cholesterol; TGs: triglycerides; PAI-1: plasminogen activator inhibitor-1; BNP: brain natriuretic peptide; eGFR: estimated glomerular filtration rate; IFNL3: interferon-λ3.